These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 16700890)

  • 1. Antisense oligonucleotides: from design to therapeutic application.
    Chan JH; Lim S; Wong WS
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats.
    Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY
    Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design.
    Delihas N; Rokita SE; Zheng P
    Nat Biotechnol; 1997 Aug; 15(8):751-3. PubMed ID: 9255788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
    Mahato RI; Cheng K; Guntaka RV
    Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
    Zhao X; Pan F; Holt CM; Lewis AL; Lu JR
    Expert Opin Drug Deliv; 2009 Jul; 6(7):673-86. PubMed ID: 19552611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
    Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
    Liu Y; Franzen S
    Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense effects in the cell nucleus: modification of splicing.
    Kole R; Sazani P
    Curr Opin Mol Ther; 2001 Jun; 3(3):229-34. PubMed ID: 11497345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
    Opalinska JB; Kalota A; Gifford LK; Lu P; Jen KY; Pradeepkumar PI; Barman J; Kim TK; Swider CR; Chattopadhyaya J; Gewirtz AM
    Nucleic Acids Res; 2004; 32(19):5791-9. PubMed ID: 15514112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis.
    Dong L; Zuo L; Xia S; Gao S; Zhang C; Chen J; Zhang J
    J Gene Med; 2009 Mar; 11(3):229-39. PubMed ID: 19189285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybridization of antisense reagents to RNA.
    Sohail M; Southern EM
    Curr Opin Mol Ther; 2000 Jun; 2(3):264-71. PubMed ID: 11249620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LNA-antisense rivals siRNA for gene silencing.
    Jepsen JS; Wengel J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA modulation, repair and remodeling by splice switching oligonucleotides.
    Kole R; Williams T; Cohen L
    Acta Biochim Pol; 2004; 51(2):373-8. PubMed ID: 15218534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.